ArQule Inc.
19 Presidential Way
Woburn,
MA 01801
United States - Map
Phone: 781-994-0300
Fax: 781-376-6019
Web Site: http://www.arqule.com
| ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets. Its lead product ARQ 197 is an orally administered inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in microphthalmia transcription factor associated tumors, non-small cell lung cancer, pancreatic adenocarcinoma, and hepatocellular carcinoma. The companys clinical stage products also include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. Its preclinical and discovery programs comprise ARQ 621 focused on inhibition of the Eg5 kinesin spindle protein; ARQ 761, a second-generation E2F-1 activator; and BRAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Paolo Pucci , 47
Chief Exec. Officer |
$
675.00K | N/A | Mr. Peter S. Lawrence J.D., 46
Pres, Chief Operating Officer and Prinicipal Financial Officer |
N/A
| N/A | Dr. Brian Schwartz M.D., 47
Chief Medical Officer and Sr. VP |
$
197.00K | N/A | Dr. Thomas C. K. Chan Ph.D., 53
Chief Scientific Officer and Sr. VP |
$
361.00K | N/A | Mr. Robert J. Weiskopf , 58
Principal Accounting Officer, VP of Fin., Treasurer and Corp. Controller |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
0.14%
Profile
